US2022280496A1PendingUtilityA1
Processes of making and crystalline forms of a mdm2 inhibitor
Est. expiryJun 10, 2033(~6.9 yrs left)· nominal 20-yr term from priority
Inventors:Matthew BioSebastien CailleBrian CochranYuanqing FangBrian M. FoxBrian Stuart LucasLawrence R. McgeeFilisaty VounatsosSean H. WiedemannSarah Wortman
C07B 2200/13A61P 35/00A61K 31/45C07C 309/25C07D 491/048C07D 211/76C07D 498/04C07C 309/35C07C 309/04C07C 313/02A61K 31/451C07D 211/94A61P 43/00A61P 35/02
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
Claims
exact text as granted — not AI-modified1 - 12 . (canceled)
13 . A process for making
the process comprising: reacting
under dehydrating conditions with
to form
14 . The process of claim 14 , wherein the dehydrating conditions are azeotropic distillation with toluene.
15 . A process of making
the process comprising: reacting
with
to form
wherein X is CF 3 SO 3 − or
16 . (canceled)
17 . (canceled)
18 . A process of making
the process comprising reacting
in presence of a base, to form
oxidizing
to form
which is further converted to
19 .- 38 . (canceled)
39 . The process of claim 18 , wherein the base is sodium tert-butoxide.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.